6-吗啉代苯并[D]噻唑-2-胺 | 94641-22-2

• 物质功能分类: 香精与香料 - 合成香料 - 内酯和含氧杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 6-吗啉代苯并[D]噻唑-2-胺
• 英文名称: 6-morpholinobenzo[d]thiazol-2-amine
• 英文别名: 6-morpholino-2-aminobenzothiazole；6-morpholin-4-yl-benzothiazol-2-amine；6-morpholin-4-yl-1,3-benzothiazol-2-amine
• CAS: 94641-22-2
• 化学式: C₁₁H₁₃N₃OS
• mdl: MFCD03848248
• 分子量: 235.31
• InChiKey: JDHQHFVILFUOFG-UHFFFAOYSA-N

物化性质

• 沸点：
  452.5±55.0 °C(Predicted)
• 密度：
  1.369±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  79.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338,P304+P340,P405
• 危险性描述：
  H302
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  6-吗啉代苯并[D]噻唑-2-胺 在 吡啶 、 一水合肼 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 12.5h， 生成 (E)-N-(6-morpholinobenzo[d]thiazol-2-yl)-2-(4-(4-tert-butylbenzyloxy)-2-hydroxybenzylidene)hydrazinecarboxamide
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents

  摘要：

  A series of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety were designed and synthesized and their cytotoxic activities against five cancer cell lines (NCI-H226, SK-N-SH, HT29, MKN45, and MDA-MB-231) were screened in vitro. Most of them showed moderate to excellent activity against all the tested cell lines. Among them, compounds 15g (procaspase-3 EC50 = 1.42 mu M) and 16b (procaspase-3 EC50 = 0.25 mu M) exhibited excellent antitumor activity with IC50 values ranging from 0.14 mu M to 0.98 mu M against all cancer cell lines, which were 1.8-8.7 times more active than the first procaspase activating compound (PAC-1) (procaspase-3 EC50 = 4.08 mu M). The structure activity relationship (SAR) analyses indicated that the introduction of a lipophilic group (a benzyloxy or heteroaryloxy group) at the 4-position of the 2-hydroxy phenyl ring was beneficial to antitumor activity, and the presence of substituents containing nitrogen that are positively charged at physiological pH could also improve antitumor activity. It was also confirmed that the steric effect of the 4-position substituent of the benzyloxy group had a significant influence on cytotoxic activity. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.08.058
• 作为产物：
  描述：

  对硝基氯苯 在 iron(III) chloride hexahydrate 、 溴 、 甲烷 、 一水合肼 、 溶剂黄146 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 8.0h， 生成 6-吗啉代苯并[D]噻唑-2-胺
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents

  摘要：

  A series of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety were designed and synthesized and their cytotoxic activities against five cancer cell lines (NCI-H226, SK-N-SH, HT29, MKN45, and MDA-MB-231) were screened in vitro. Most of them showed moderate to excellent activity against all the tested cell lines. Among them, compounds 15g (procaspase-3 EC50 = 1.42 mu M) and 16b (procaspase-3 EC50 = 0.25 mu M) exhibited excellent antitumor activity with IC50 values ranging from 0.14 mu M to 0.98 mu M against all cancer cell lines, which were 1.8-8.7 times more active than the first procaspase activating compound (PAC-1) (procaspase-3 EC50 = 4.08 mu M). The structure activity relationship (SAR) analyses indicated that the introduction of a lipophilic group (a benzyloxy or heteroaryloxy group) at the 4-position of the 2-hydroxy phenyl ring was beneficial to antitumor activity, and the presence of substituents containing nitrogen that are positively charged at physiological pH could also improve antitumor activity. It was also confirmed that the steric effect of the 4-position substituent of the benzyloxy group had a significant influence on cytotoxic activity. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.08.058

文献信息

• Imidazolothiazole compounds for the treatment of disease
  申请人：Bhagwat Shripad

  公开号：US20070232604A1

  公开（公告）日：2007-10-04

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  提供了用于调节受体激酶活性以及用于治疗、预防或改善由受体激酶介导的一种或多种疾病或紊乱症状的化合物、组合物和方法。
• Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold
  作者：Guanglong Bao、Baoquan Du、Yuxiu Ma、Meng Zhao、Ping Gong、Xin Zhai

  DOI：10.2174/1573406412666160107113343

  日期：2016.6.23

  Two series of novel benzothiazole derivatives conjugated with semicarbazone scaffold were designed and synthesized through a structure-based molecular hybridization strategy. All the target compounds were evaluated for their cytotoxicity in vitro against three cancer cell lines (HT-29, MKN-45 and H460) by standard MTT assay. The pharmacological results indicated that seven compounds (17h-n) exhibited

  通过基于结构的分子杂交策略，设计并合成了两类新颖的结合了半脲酮骨架的苯并噻唑衍生物。通过标准MTT测定法评估了所有目标化合物在体外对三种癌细胞系（HT-29，MKN-45和H460）的细胞毒性。药理结果表明，与参考药物索拉非尼和PAC-1相比，七种化合物（17h-n）表现出可比甚至更好的抗增殖活性。尤其是，化合物17i对测试的三种癌细胞系表现出显着的细胞毒性，IC50值分别为0.84、0.06和0.52 µM，分别比索拉非尼强4.3倍，36.6倍，4.2倍，并且比索拉非尼高1.2倍，13.7倍，6.9倍分别比PAC-1活跃。
• Method of using imidazolothiazole compounds for the treatment of disease
  申请人：Ambit Bioscience Corporation

  公开号：US08129374B2

  公开（公告）日：2012-03-06

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  提供了化合物、组合物和方法，用于调节受体激酶的活性，以及治疗、预防或改善由受体激酶介导的一种或多种疾病或障碍的症状。
• IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE
  申请人：Bhagwat Shripad

  公开号：US20120129850A1

  公开（公告）日：2012-05-24

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  提供了化合物、组合物和方法，用于调节受体激酶的活性，并用于治疗、预防或减轻由受体激酶介导的一种或多种疾病或障碍的症状。
• METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE
  申请人：Bhagwat Shripad

  公开号：US20100298313A1

  公开（公告）日：2010-11-25

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  本发明提供了化合物、组合物和方法，用于调节受体激酶的活性，并用于治疗、预防或改善由受体激酶介导的一种或多种疾病或障碍的症状。